13-Methoxy-LSD

13-Methoxy-LSD
Clinical data
Other names	13-Methoxylysergic acid diethylamide; 13-OMe-LSD; 13-MeO-LSD; N,N-Diethyl-13-methoxy-6-methyl-9,10-didehydroergoline-8β-carboxamide
ATC code	None;
Identifiers
	IUPAC name N,N-diethyl-2-methoxy-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide;
PubChem CID	156727595;
Chemical and physical data
Formula	C21H27N3O2
Molar mass	353.466 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCN(CC)C(=O)C1CN(C2CC3=CNC4=CC(=CC(=C34)C2=C1)OC)C;
	InChI InChI=1S/C21H27N3O2/c1-5-24(6-2)21(25)14-7-16-17-9-15(26-4)10-18-20(17)13(11-22-18)8-19(16)23(3)12-14/h7,9-11,14,19,22H,5-6,8,12H2,1-4H3; Key:NFQMBWPVBDJETC-UHFFFAOYSA-N;

13-Methoxy-LSD is a lysergamide related to lysergic acid diethylamide (LSD).^[1] It is the derivative of LSD with a methoxy group at the 13 position and is the O-methyl ether of 13-hydroxy-LSD.^[1] Similarly to 13-hydroxy-LSD and other related compounds like 12-hydroxy-LSD and 12-methoxy-LSD, 13-methoxy-LSD has been reported to produce LSD-like electroencephalogram (EEG) changes in rabbits.^[1] Conversely, 14-methoxy-LSD was inactive.^[1] 13-Methoxy-LSD was first described in the scientific literature by 1979.^[1]

Quick Facts Clinical data, Other names ...

See also